RT Journal Article
SR Electronic
T1 Comparison of primer-probe sets among different master mixes for laboratory screening of Severe Acute Respiratory Syndrome - Coronavirus 2 (<em>SARS-CoV-2</em>)
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.20.20136242
DO 10.1101/2020.06.20.20136242
A1 Cuong, Hoang Quoc
A1 Hai, Nguyen Duc
A1 Linh, Hoang Thuy
A1 Anh, Nguyen Hoang
A1 Hieu, Nguyen Trung
A1 Thang, Cao Minh
A1 Thanh Thao, Nguyen Thi
A1 Lan, Phan Trong
YR 2020
UL http://medrxiv.org/content/early/2020/06/22/2020.06.20.20136242.abstract
AB Background The shortage of chemical reagents for severe acute respiratory syndrome - coronavirus 2 (SARS-CoV-2) diagnosis and the surge of SARS-CoV-2 cases, especially in limited resource settings. Therefore, the combination of an optimal assay kit is necessary.Methods We compared the ability to screen SARS-CoV-2 among three primer-probe sets added into two different master mixes (Invitrogen™ SuperScript™ III One-Step RT-PCR, and LightCycler Multiplex RNA Virus Master).Results The assay with TIB-Molbiol, IDT, and Phu Sa sets for LightCycler Multiplex RNA Virus Master or Invitrogen™ SuperScript™ III One-Step RT-PCR showed positive results from a single reaction of triplicate in the three days of 4.8 copies per reaction, with R-square and amplification efficiently (AE) were 0.97 and ranged from 107 to 108%, respectively.Conclusions Our findings indicated TIB-Molbiol, IDT, and Phu Sa primer-probe sets could be beneficial for the laboratory screening of SARS-CoV-2 by Realtime RT-PCR assay of E gene. There is a need for considering the combination of these reagent sets as a new strategy to increase testing capacity for screening programs for COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research received no external funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Study protocol has been reviewed and ratified by the Pasteur Institute Ho Chi Minh City Institutional Review Board (reference number: 433/XN-PAS). The clinical trial involved have been registered.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data used to support the findings of this study are available from the corresponding author upon request. AbbreviationRT-PCRReverse transcription polymerase chain reactionSARS-CoV-2Severe Acute Respiratory Syndrome Coronavirus 2COVID-19Corona virus infected diseases 19